In early August, Triangle Pharmaceuticals Inc.'s stock shot up surrounding favorable interim data from a Phase III trial of the company's lead product candidate for HIV. And Thursday, the stock was up again when Triangle said it had taken the positive data and filed its first new drug application. (Bioworld Today)
In early August, Triangle Pharmaceuticals Inc.'s stock shot up surrounding favorable interim data from a Phase III trial of the company's lead product candidate for HIV. And Thursday, the stock was up again when Triangle said it had taken the positive data and filed its first new drug application. (Bioworld Today)
